WordNet

a substance that exerts some force or effect
a businessman who buys or sells for another in exchange for a commission (同)factor, broker
any agent or representative of a federal agency or bureau (同)federal agent
a representative who acts on behalf of other persons or organizations
an active and efficient cause; capable of producing a certain effect; "their research uncovered new disease agents"
how long something has existed; "it was replaced because of its age"
a time of life (usually defined in years) at which some particular qualification or power arises; "she was now of school age"; "tall for his eld" (同)eld
begin to seem older; get older; "The death of his wife caused him to age fast"
make older; "The death of his child aged him tremendously"

PrepTutorEJDIC

『代理人』;周旋人 / 働き(作用)を起こすもの;作用物,薬剤 / (政府機関,特にFBI,CIAなどの)部員,機関員
〈U〉(一般に)『年齢』,寿命;〈C〉(個々の)『年齢』,年 / 〈U〉成年(おとなとしての資格・権利を得る年齢;通例18または21歳) / 〈U〉『老齢』;《集合的に》老人たち / 〈U〉(人生の)『一時期』;〈C〉世代(generation) / 〈U〉〈C〉《しばしばA-》(歴史上の)『時代』 / 〈C〉《話》長い間 / 年をとる,ふける;〈物が〉古くなる / 〈年〉'を'とらせる;〈物〉'を'古びさせる

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

Lally SE1.
Current opinion in ophthalmology.Curr Opin Ophthalmol.2016 May 23. [Epub ahead of print]
PURPOSE OF REVIEW: The purpose of this article is to review the recent published literature in 2015 on lymphatic malformation and provide updated information on the disease. Specifically, this article will describe recent advances in identifying and managing lymphatic malformations.RECENT FINDINGS:
PMID 27219273

A pilot study-is there a role for mitoxantrone pleurodesis in the management of pleural effusion due to lung cancer?

Sreter KB1, Jakopovic M1, Janevski Z1, Samarzija M1, Zarogoulidis P1, Kioumis I1, Mparmpetakis N1, Pataka A1, Zarogoulidis K1, Tsiouda T1, Kosmidis C1, Mpaka S1, Huang H1, Hohenforst-Schmidt W1, Charalampidis C1, Machairiotis N1, Zaric B1, Milovancev A1.
Annals of translational medicine.Ann Transl Med.2016 May;4(9):162. doi: 10.21037/atm.2016.04.15.
BACKGROUND: Lung cancer is the leading cause of malignant pleural effusion (MPE). Management of MPEs remains a clinical challenge due to recurrence and poor quality of life. An ideal sclerosing agent has yet to be found. The aim of this cohort pilot study was to evaluate the role of mitoxantrone ple
PMID 27275475

Clinical outcome and predictors of treatment response in foam sodium tetradecyl sulfate sclerotherapy of venous malformations.

Park HS1, Do YS2, Park KB1, Kim KH1, Woo SY3, Jung SH4, Kim DI5, Kim YW5, Hyun D1, Cho SK1, Choo IW1.
European radiology.Eur Radiol.2016 May;26(5):1301-10. doi: 10.1007/s00330-015-3931-9. Epub 2015 Aug 26.
OBJECTIVES: To evaluate clinical outcomes and their predictors in patients with venous malformation (VM) treated with foam sodium tetradecyl sulfate (STS) sclerotherapy.METHODS: We retrospectively evaluated clinical outcomes of foam STS sclerotherapy in 86 patients with 91 VMs to assess reduction in
PMID 26307182

A Novel Peptide Derived from the Fusion Protein Heptad Repeat Inhibits Replication of Subacute Sclerosing Panencephalitis Virus In Vitro and In Vivo

IS-3-7 Is multiple session of intralesional sclerosing agent is must in congenital lymphatic malformation?(IS-3 International Session (3) Pediatric surgery)